Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
Abstract The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, we established a cohort of 434 Chinese patients with...
Main Authors: | Lei-Jie Dai, Ding Ma, Yu-Zheng Xu, Ming Li, Yu-Wei Li, Yi Xiao, Xi Jin, Song-Yang Wu, Ya-Xin Zhao, Han Wang, Wen-Tao Yang, Yi-Zhou Jiang, Zhi-Ming Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-40715-x |
Similar Items
-
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
by: Lei-Jie Dai, et al.
Published: (2023-10-01) -
Breast cancer screening and early diagnosis in Chinese women
by: Rui Ding, et al.
Published: (2022-04-01) -
HER2 gene amplification in HER2 2+ breast cancer and its clinicopathological characteristics
by: Dan Wan, et al.
Published: (2023-02-01) -
Clinicopathological features and prognosis of patients with HER2-low breast cancer
by: Xin Yang, et al.
Published: (2023-09-01) -
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
by: Liu Yang, et al.
Published: (2022-04-01)